Sofosbuvir plus Ribavirin for the Treatment of HCV Genotype 2 Infection: Results of the Real-World, Clinical Practice HCV-TARGET Study (G2)
Tania M. Welzel1, David R. Nelson2, Giuseppe Morelli; Adrian Di Bisceglie; Raj Reddy; Alexander Kuo; Joseph K. Lim; Jama Darling; Paul Pockros; Joseph Galati; Lynn M. Frazier; Saleh Alqahtani; Mark S. Sulkowski; Monika Vainorius, Lucy Akushevich, Michael W. Fried; Stefan Zeuzem1
Effectiveness of Ledipasvir-sofosbuvir Combination in Patients with Hepatitis C Virus Infection and Factors Associated of Sustained Virologic Response
Norah Terrault, Stefan Zeuzem, Adrian M Di Bisceglie, Joseph K Lim, Paul J Pockros, Lynn M Frazier, Alexander Kuo, Anna S Lok, Mitchell L Shiffman, Ziv Ben Ari, Lucy Akushevich, Monika Vainorius, Mark S Sulkowski, Michael W Fried, David R Nelson
Effectiveness and safety of sofosbuvir-based regimens for the treatment of chronic hepatitis C virus genotype 3 infection: results of the HCV-TARGET study (G3)
Safety and Efficacy of Sofosbuvir-Containing Regimens in Hepatitis C Infected Patients with Reduced Renal Function
Varun Saxena1; Farrukh M. Koraishy2, Meghan Sise3, Joseph K. Lim4, Monica Schmidt5, Raymond T. Chung3, Annmarie Liapakis4, David R. Nelson6, Michael W. Fried5, Norah Terrault1 and HCV-TARGET
Interferon-free Therapy for Genotype 1 Hepatitis C in Liver Transplant Recipients: Real World Experience from HCV-TARGET
Robert S. Brown, Jr., M.D., M.P.H1., Jacqueline G. O’Leary M.D2, K. Rajender Reddy M.D3, Alexander Kuo4, Giuseppe Morelli5, R. Todd Stravitz6, Christine Durand7, Adrian M. Di Bisceglie8, Hugo E. Vargas9, Paul Kwo10, Catherine T. Frenette11, Thomas G. Stewart12, David R. Nelson5, Michael W. Fried12, and Norah Terrault M.D13 on behalf of HCV-TARGET Study Group
Effectiveness of Simeprevir plus Sofosbuvir with or without ribavirin for the treatment of patients with HCV genotype 1 infection in real-world clinical practice: The HCV TARGET Study
Sulkowski MS1, Vargas HE, Di Bisceglie AM, Kuo, PA, Reddy KR, Lim JK, Morelli G, Darling JM, Feld JJ, Brown RS, Frazier LM, Stewart TG, Fried MW, Nelson DR, and Jacobson IM for the HCV-TARGET Study Group
VIROLOGIC OUTCOMES AND ADHERENCE TO TREATMENT ALGORITHMS IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH BOCEPREVIR OR TELAPREVIR
Richard K. Sterling,1 Alexander Kuo,2 Vinod K Rustgi,3 Mark S. Sulkowski,4 Thomas G. Stewart,5 Jonathan M. Fenkel,6 Hisham El-Genaidi,7 Mitchell A. Mah’moud,8 George M. Abraham,9 Paul Stewart, David R. Nelson, Michael W. Fried,5 Adrian M. Di Bisceglie10 for the HCV-TARGET Study Group
Adverse Events With Boceprevir or Telaprevir in Chronic Hepatitis C: Real-World Experience From HCV-TARGET.
Stuart C. Gordon, MD,1* Andrew J. Muir, MD, MHS,2 Joseph K. Lim, MD,3 Brian Pearlman, MD,4 Curtis K. Argo, MD,5 Ananthakrishnan Ramani, MD,6 Benedict Maliakkal, MD,7 Imtiaz Alam,8 Thomas G. Stewart, MD,9 Monika Vainorius, MD,9 Joy Peter, RN,10 David R. Nelson, MD,10 Michael W. Fried, MD,9 K. Rajender Reddy, MD,11* for the HCV-TARGET Study Group
Successful therapy of Hepatitis C with daclatasvir, pegylated interferon and ribavirin after failure with boceprevir based therapy in a liver transplant recipient with hyper-IgM syndrome
K.Rajender Reddy, Amina Wirjosemito, Lorie Sinese, Eric Hughes, Patricia Mendez
Recent Comments